Ask a Question

User lyreflax33

Member for: 1 week (since Aug 19)
Type: Registered user
Full name:
Location:
Website: https://www.selleckchem.com/products/cu-cpt22.html
About: A Period I, Open-Label, Dose-Escalation Research from the OX40 Agonist Ivuxolimab in Patients Using Locally Innovative or Metastatic Cancers.

Activity by lyreflax33

Score: 100 points (ranked #49)
Questions: 0
Answers: 0
Comments: 0
Voted on: 0 questions, 0 answers
Gave out: 0 up votes, 0 down votes
Received: 0 up votes, 0 down votes

Wall for lyreflax33

Please log in or register to post on this wall.
Snow Theme by Q2A Market
Powered by Question2Answer
...